Tumor-Secreted Protein May Hold the Key to Better Treatments for Deadly Brain Tumor Jan. 8, 2025 — A study has found targeting a protein called endocan and its related signaling pathway could be ...

Today, a brief rundown of news involving Merck & Co. and AstraZeneca, as well as updates from AbbVie, Stealth BioTherapeutics and Vigil Neuroscience that you may have missed. Patents protecting ...

Merck & Co. and Eisai have to deal with the reality that yet another phase 3 trial of their combination of Keytruda and Lenvima didn’t exactly go their way. The Keytruda-Lenvima regimen ...

MSD’s checkpoint inhibitor Keytruda has been cleared by the FDA for use in newly diagnosed cervical cancer patients with less severe disease, becoming the first anti-PD-1/PD-L1 immunotherapy for ...

“Keytruda is not for everyone,” says Dr. Anna Pavlick, medical oncologist at Weill Cornell Medicine. She often has patients request the immunotherapy drug in response to a commercial they’ve seen. It ...

with no EGFR or ALK genomic tumor aberrations, is indicated for the treatment of adult and pediatric patients with refractory classical Hodgkin lymphoma (cHL), or who have relapsed after 3 or more ...

Prostate cancer has proved an elusive target for cancer immunotherapies, and Merck & Co's checkpoint inhibitor Keytruda is the latest to fall short in the disease in a phase 3 trial. Merck has ...

Merck’s mega blockbuster Keytruda paired with Eisai’s Lenvima did not improve overall survival in a Phase III clinical trial of patients with an advanced form of gastroesophageal adenocarcinoma. While ...

In extending patent protection for its primary cancer medication, Keytruda, Merck (NYSE:MRK) intends to introduce a subcutaneous form of it this year. It's important to also note that Merck is ...

The word tumor is an umbrella term for a cancerous mass, which means an uncontrolled replication or growth of cells, says Dr. Joseph Tsang, D.V.M. and senior veterinarian at Small Door Veterinary.

Merck & Co. expects to launch an easier-to-administer version of its blockbuster cancer treatment Keytruda before the end of the year, accelerating the company’s efforts to protect its top ...

The com­bi­na­tion of Mer­ck’s Keytru­da and Ei­sai’s Lenvi­ma failed to pro­long pa­tients’ lives ver­sus the com­para­tor in an­oth­er can­cer study, but the com­pa­nies ...